关键词: microrna expression
来源: 互联网
3184 阅读
The gene expression patterns of tumor-derived cell lines differ greatly, as do their responses to antiproliferative effects of interferons (IFNs). The cause of this variation has been under investigation for more than 40 years, but only basic regulatory mechanisms of interferon signaling are understood today. Small regulatory genome encoded RNAs, such as microRNAs, have recently attracted attention in genomic research. New methods to analyze the levels of these regulatory elements are now commercially available, but the power of these techniques is still discussed extensively. Our study was designed to compare two methods for microRNA detection with respect to usefulness in defined cell culture assays. The experimental design assesses variation between the two cell lines and the treatment effects of IFNα.
A hallmark of the therapeutic activity of type I interferons is the induction of antiproliferative activity mediated by the upregulation of several hundred response genes with pleiotropic functions (1). These genes can be divided into two major classes based on the kinetic properties of induction (2). Primary response genes (PRGs) are upregulated within 24 h after the cytokine signal and the secondary response genes (SRGs) are induced following day 1 when the activity of the PRGs decays. In contrast to SRGs, all PRGs studied to date contain bona fide interferon response elements in the promoter region, which are required for binding of the interferon-stimulated gene factor 3 (ISGF3) complex and for janus kinase/signal transducer of transcription (JAK/STAT)-pathway-mediated signaling.
Expression of PRGs is turned off by proteins termed suppressors of cytokine signaling (SOCS) (3). As the nomenclature indicates, this class of polypeptides has the capacity to interfere and silence other cytokine-induced signaling cascades (for review see (4)). SOCS1 for instance is part of the early inducible PRG cluster and down modulation occurs together with the other genes before onset of SRG expression. It is believed that feedback inhibition of JAK/STAT signaling by SOCS1 represses transcriptome modulation of IFNα signaling (5). Regulation of SOCS protein translation by interferon-regulated microRNAs (IRmiRs) would enhance the potential of cytokine fine regulation. It has been reported that miR-19 antagonists lead to higher SOCS1 levels and miR-19 mimics can repress SOCS1 reporter constructs, thus obviously supporting the bioinformatic predictions that SOCS1 is a direct target of miR-19 (6). Inhibition of SOCS activity could for instance prolong the duration of cytokine activity, which has obvious clinical implications.
Following the discovery of microRNAs in virtually all higher eukaryotic organisms significant research efforts were initiated to address the function of these catalytic oligonucleotides which are the natural counterparts of synthetic small inhibitory RNAs (siRNAs) used for experimental gene silencing (for review see (7)). MicroRNAs are positive and negative modulators of the expression of entire gene clusters that contain complementary microRNA recognition sequence motifs in the 3′-UTR. Today, prediction of microRNA target genes by homology-based algorithms is still ambiguous (8). The activity of one or several microRNAs could explain suppression of the entire PRG cluster provided that microRNA abundance is regulated by IFNα. Alternatively, microRNA-mediated degradation of transcripts encoding negative regulatory proteins would also abolish PRG expression and restore IFNα responsiveness.
Some recent reports showed that interferon beta (IFNβ) stimulation can boost microRNA levels in cell culture together with inhibition of viral replication (9). At this point it is an open question whether this induction is IFNβ specific or a shared feature of all type I interferons. To investigate whether microRNA are also involved in regulation of IFNα response, we used two human-tumor-derived cell lines: the melanoma line ME-15 (10) and the hepatoma line HuH7 (11). We have chosen these cell lines as models, because we have a good understanding of the IFNα responses at the mRNA and the protein levels in these cell lines. Further we chose to use a melanoma cell line because IFN is also used for treatment of this cancer type. HuH7 is commonly used as a model for testing antiviral effects of IFN in the HCV replicon system. In both models efficient responses to IFNα have been shown at the functional and transcriptional level. IFNα response genes carry response elements in their promoter region and these motifs are responsible for gene expression with similar efficiency in many cell types. Therefore we expected to find a similar regulated set of genes in both lines given that IRmiR genes are regulated by the same mechanism, whereas some constitutively expressed microRNA genes were expected to be cell type specific for functional reasons. We have chosen a DNA-microarray-based technology (Illumina) for the multi-parallel expression analysis of all known human microRNAs (http://microrna.sanger.ac.uk/; Release 10.0: August 2007). This method allowed us to process total RNA as template, allowing the possibility of mRNA gene expression profiling in further experiments. Briefly, annealing of microRNA specific primers combined with enzymatic polyadenylation allows multi-parallel polymerase chain reaction (PCR)-mediated amplification of individual microRNAs. The output of this step is a DNA amplicon library that reflects to a large extent the original stoichiometry of mature microRNAs in a cell or tissue (12). PCR amplification is performed with fluorescently labeled primers, which allows quantitative signal detection by conventional confocal laser scanning.
Melanoma cells (ME-15) were cultured in RPMI 1640 with L-Glutamine supplemented with non-essential amino acids and sodium pyruvate (1 mM) and hepatoma (HuH7) cells were cultured in DMEM + GlutaMAX. Both media contained 10% FBS. All cell culture reagents were purchased from Invitrogen (GIBCO®). Roferon (Interferon alpha2a, ROCHE) was diluted in fresh medium to a final concentration of 1,000 U/mL and control cultures were grown without cytokine. Cells were cultured at 37°C in a humidified atmosphere containing 5% CO2. Total RNA preparation was carried out using TRIZOL (Invitrogen) total RNA extraction using 1/2 volume of 1-bromo-3-chloro-propane (molecular biology grade, SIGMA) as chloroform substitute. For efficient recovery of small RNAs, DNA LoBind tubes (Eppendorf) were used and all centrifugation steps were performed at maximum speed and 4°C in an Eppendorf 5417R centrifuge. Total RNA was precipitated with 2 vol of 2-propanol (Fluka) at −20°C for at least 16 h. The RNA pellet was washed with 75% ethanol (Merck), dried, and dissolved in DEPC-treated water (Ambion). The RNA was quantified with Quant-iT™ RiboGreen® RNA Assay (Invitrogen) as suggested by Illumina.
Starting with 500 ng/sample of total RNA, mature microRNAs were amplified with the Illumina human v1 MicroRNA expression profiling kit containing primers for 743 human microRNAs. The resulting amplicons were hybridized to a 96 sample universal probe capture array and fluorescent signals were detected by confocal laser scanning. All steps were performed according to Illumina’s instructions manual.
|
Control |
Interferon-alpha treated |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 h |
24 h |
4 h |
24 h |
||||||||||
ME-15 |
HuH7 |
CHF |
ME-15 |
HuH7 |
CHF |
ME-15 |
HuH7 |
CHF |
ME-15 |
HuH7 |
CHF |
||
microRNAs rated higher in HuH7 |
|||||||||||||
hsa-miR-122a |
685 |
30,912 |
44.14*** |
704 |
32,058 |
44.51*** |
717 |
30,459 |
41.46*** |
876 |
29,044 |
32.17*** |
|
hsa-miR-224 |
359 |
10,085 |
27.07*** |
345 |
7,358 |
20.31*** |
358 |
8,183 |
21.87*** |
333 |
7,483 |
21.44*** |
|
hsa-miR-483 |
915 |
23,671 |
24.87*** |
811 |
18,073 |
21.29*** |
849 |
17,784 |
19.95*** |
802 |
17,554 |
20.88*** |
|
hsa-miR-200a |
517 |
8,392 |
15.22*** |
667 |
13,543 |
19.29*** |
722 |
11,317 |
14.68*** |
500 |
12,649 |
24.30*** |
|
hsa-miR-218 |
405 |
5,654 |
12.96*** |
417 |
6,527 |
14.64*** |
419 |
5,764 |
12.76*** |
431 |
6,155 |
13.29*** |
|
hsa-miR-618 |
700 |
7,549 |
9.78*** |
649 |
8,128 |
11.52*** |
651 |
8,042 |
11.35*** |
616 |
7,416 |
11.03*** |
|
hsa-miR-215 |
638 |
6,826 |
9.71*** |
829 |
6,013 |
6.25*** |
663 |
6,641 |
9.02*** |
723 |
6,501 |
7.99*** |
|
hsa-miR-192 |
3,956 |
34,724 |
7.78*** |
3,401 |
34,181 |
9.05*** |
4,021 |
29,382 |
6.31*** |
3,343 |
33,293 |
8.96*** |
|
hsa-miR-194 |
4,410 |
32,950 |
6.47*** |
4,142 |
32,991 |
6.96*** |
4,700 |
33,182 |
6.06*** |
4,410 |
32,422 |
6.35*** |
|
hsa-miR-182 |
1,575 |
11,480 |
6.29 *** |
2,541 |
13,088 |
4.15*** |
2,227 |
12,512 |
4.62*** |
3,067 |
13,907 |
3.53*** |
|
hsa-miR-452 |
434 |
2,284 |
4.27*** |
707 |
3,326 |
3.70*** |
530 |
3,378 |
5.37*** |
636 |
3,028 |
3.76*** |
|
hsa-miR-183 |
1,763 |
8,748 |
3.96*** |
2,123 |
8,945 |
3.21*** |
2,000 |
8,984 |
3.49*** |
2,129 |
8,258 |
2.88*** |
|
hsa-miR-200b |
1,934 |
7,551 |
2.90*** |
1,692 |
9,633 |
4.69*** |
1,705 |
9,393 |
4.51*** |
1,911 |
10,855 |
4.68*** |
|
hsa-miR-143 |
1,355 |
5,087 |
2.75*** |
1,775 |
7,167 |
3.04*** |
1,698 |
5,688 |
2.35*** |
1,765 |
7,519 |
3.26*** |
|
hsa-miR-624 |
4,852 |
13,418 |
1.77** |
4,188 |
11,593 |
1.77*** |
4,479 |
11,718 |
1.62** |
3,872 |
10,539 |
1.72** |
|
hsa-miR-99a |
8,653 |
20,232 |
1.34** |
8,887 |
20,645 |
1.32*** |
9,064 |
18,019 |
0.99** |
8,870 |
19,506 |
1.20** |
|
hsa-miR-27b |
10,067 |
22,544 |
1.24** |
11,924 |
23,914 |
1.01*** |
11,564 |
23,044 |
0.99*** |
12,182 |
24,515 |
1.01** |
|
microRNAs rated higher in ME-15 |
|||||||||||||
hsa-miR-146a |
36,976 |
15,721 |
−1.35** |
33,410 |
16,103 |
−1.07*** |
35,166 |
15,137 |
−1.32*** |
35,688 |
19,962 |
−0.79*** |
|
hsa-miR-422b |
19,264 |
7,759 |
−1.48** |
19,962 |
7,832 |
−1.55*** |
20,641 |
7,462 |
−1.77*** |
17,453 |
7,152 |
−1.44*** |
|
hsa-miR-149 |
5,868 |
2,246 |
−1.61** |
6,195 |
2,030 |
−2.05*** |
6,061 |
1,743 |
−2.48*** |
5,477 |
2,418 |
−1.26** |
|
hsa-miR-510 |
1,051 |
368 |
−1.86*** |
1,489 |
396 |
−2.76*** |
1,435 |
366 |
−2.92*** |
1,053 |
384 |
−1.74*** |
|
hsa-miR-30a-5p |
10,664 |
3,717 |
−1.87** |
10,223 |
3,700 |
−1.76*** |
10,686 |
3,477 |
−2.07*** |
10,466 |
4,538 |
−1.31*** |
|
HS_98 |
3,274 |
1,065 |
−2.08** |
3,225 |
859 |
−2.76*** |
3,445 |
965 |
−2.57*** |
2,850 |
750 |
−2.80*** |
|
hsa-miR-340 |
4,583 |
1,443 |
−2.18** |
4,218 |
1,220 |
−2.46*** |
4,664 |
1,061 |
−3.40*** |
3,078 |
933 |
−2.30*** |
|
HS_182.1 |
1,965 |
615 |
−2.2** |
1,687 |
606 |
−1.79** |
1,903 |
562 |
−2.39*** |
1,844 |
534 |
−2.45*** |
|
hsa-miR-378 |
4,619 |
1,371 |
−2.37** |
4,975 |
1,364 |
−2.65*** |
4,994 |
1,213 |
−3.12*** |
4,188 |
1,237 |
−2.38*** |
|
HS_305_b |
4,105 |
1,207 |
−2.40* |
3,853 |
833 |
−3.63*** |
4,278 |
977 |
−3.38*** |
3,688 |
1,076 |
−2.43*** |
|
hsa-miR-505 |
1,312 |
343 |
−2.83*** |
2,070 |
342 |
−5.05*** |
2,050 |
360 |
−4.70*** |
2,030 |
362 |
−4.60*** |
|
hsa-miR-10a |
1,570 |
350 |
−3.48** |
1,592 |
350 |
−3.55*** |
1,828 |
360 |
−4.07*** |
1,880 |
352 |
−4.34*** |
|
hsa-miR-10b |
1,695 |
378 |
−3.49** |
2,929 |
371 |
−6.89*** |
3,564 |
411 |
−7.67*** |
4,297 |
382 |
−10.26*** |
|
hsa-let-7g |
10,720 |
2,302 |
−3.66** |
16,046 |
3,077 |
−4.21*** |
13,792 |
2,854 |
−3.83*** |
15,435 |
2,568 |
−5.01*** |
|
hsa-miR-584 |
11,643 |
2,261 |
−4.15*** |
12,717 |
1,873 |
−5.79*** |
12,394 |
1,912 |
−5.48*** |
12,616 |
1,674 |
−6.54*** |
|
hsa-let-7i |
11,701 |
2,255 |
−4.19** |
16,410 |
2,707 |
−5.06*** |
15,319 |
2,251 |
−5.80*** |
15,718 |
2,563 |
−5.13*** |
|
hsa-miR-330 |
9,029 |
1,653 |
−4.46*** |
9,684 |
1,670 |
−4.80*** |
9,432 |
1,397 |
−5.75*** |
7,773 |
1,380 |
−4.63*** |
|
HS_307_b |
2,453 |
444 |
−4.52*** |
4,188 |
443 |
−8.45*** |
3,669 |
407 |
−8.01*** |
3,318 |
448 |
−6.41*** |
|
hsa-miR-34c |
2,292 |
412 |
−4.56** |
3,303 |
426 |
−6.75*** |
3,524 |
381 |
−8.25*** |
2,403 |
404 |
−4.95** |
|
hsa-miR-133a |
9,270 |
1,594 |
−4.82*** |
7,942 |
1,662 |
−3.78*** |
8,488 |
1,435 |
−4.92*** |
6,495 |
1,783 |
−2.64*** |
|
hsa-miR-361 |
5,234 |
828 |
−5.32*** |
7,641 |
755 |
−9.13*** |
7,356 |
875 |
−7.41*** |
7,904 |
706 |
−10.19*** |
|
hsa-miR-508 |
2,552 |
325 |
−6.86** |
4,280 |
376 |
−10.39*** |
3,965 |
357 |
−10.09*** |
4,013 |
336 |
−10.96*** |
|
hsa-miR-9* |
8,372 |
1,039 |
−7.06*** |
10,114 |
940 |
−9.76*** |
10,027 |
1,263 |
−6.94*** |
9,948 |
843 |
−10.81*** |
|
hsa-miR-31 |
5,967 |
661 |
−8.03*** |
5,742 |
720 |
−6.97*** |
6,619 |
657 |
−9.07*** |
5,978 |
728 |
−7.21*** |
|
hsa-miR-506 |
5,855 |
625 |
−8.37*** |
6,125 |
713 |
−7.59*** |
5,916 |
665 |
−7.90*** |
5,602 |
675 |
−7.30*** |
|
hsa-miR-211 |
5,147 |
476 |
−9.81*** |
3,218 |
490 |
−5.57*** |
3,833 |
471 |
−7.14** |
5,575 |
464 |
−11.01*** |
|
hsa-miR-296 |
6,194 |
570 |
−9.86*** |
5,913 |
504 |
−10.72*** |
6,441 |
557 |
−10.57*** |
4,369 |
532 |
−7.21*** |
|
hsa-miR-598 |
4,445 |
401 |
−10.09*** |
4,475 |
386 |
−10.59*** |
4,934 |
424 |
−10.63*** |
4,127 |
367 |
−10.24*** |
|
hsa-miR-199b |
9,081 |
775 |
−10.71*** |
9,478 |
916 |
−9.35*** |
9,629 |
865 |
−10.13*** |
8,059 |
911 |
−7.85*** |
|
hsa-let-7b |
8,236 |
539 |
−14.28*** |
12,563 |
475 |
−25.44*** |
12,150 |
500 |
−23.30*** |
12,309 |
452 |
−26.24*** |
|
hsa-miR-509 |
10,413 |
536 |
−18.44*** |
10,346 |
512 |
−19.22*** |
9,966 |
548 |
−17.20*** |
9,311 |
529 |
−16.62*** |
|
hsa-miR-9 |
12,587 |
422 |
−28.85*** |
15,870 |
447 |
−34.50*** |
15,502 |
418 |
−36.09*** |
16,402 |
429 |
−37.26*** |
|
hsa-miR-514 |
12,065 |
364
−32.16***
13,112
358
−35.64***
12,201
315
−37.74***
12,355
355
−33.83***
Hybdridization controls
array_hyb_con4
6,404
7,110
0.11
7,724
6,684
−0.16
7,031
6,739
−0.04
6,964
6,746
−0.03
array_hyb_con3
6,923
7,681
0.11
7,833
7,368
−0.06
7,422
7,054
−0.05
6,906
7,365
0.07
array_hyb_con1
10,779
11,868
0.10
11,812
11,728
−0.0.01
11,436
11,382
0.00
11,059
11,522
0.04
array_hyb_con2
10,258
11,145
0.09
11,382
10,829
−0.05
11,075
10,650
−0.04
9,997
10,283
0.03
Control |
Interferon-alpha treated |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 h |
24 h |
4 h |
24 h |
||||||||||
a |
ME-15 |
HuH7 |
CHF |
ME-15 |
HuH7 |
CHF |
ME-15 |
HuH7 |
CHF |
ME-15 |
HuH7 |
CHF |
|
Validated microRNAs |
|||||||||||||
hsa-miR-19a |
13,617 |
6,726 |
−1.02 |
18,318 |
17,178 |
−0.07 |
19,226 |
17,409 |
−0.10 |
14,425 |
14,079 |
−0.02 |
|
hsa-miR-19b |
13,365 |
9,406 |
−0.42 |
25,463 |
22,438 |
−0.13 |
21,532 |
20,625 |
−0.04 |
18,039 |
17,440 |
−0.03 |
|
hsa-miR-30e-5p |
9,497 |
6,838 |
−0.39 |
13,045 |
11,321 |
−0.15 |
12,643 |
10,887 |
−0.16 |
13,230 |
11,809 |
−0.12 |
|
hsa-let-7a |
15,244 |
4,335 |
−2.52. |
28,304 |
6,181 |
−3.58 *** |
22,226 |
6,386 |
−2.48*** |
30,449 |
5,612 |
−4.43*** |
|
hsa-let-7b |
8,236 |
539 |
−14.28*** |
12,563 |
475 |
−25.44*** |
12,150 |
500 |
−23.30 *** |
12,309 |
452 |
−26.24*** |
|
hsa-miR-203 |
907 |
325 |
−1.79** |
1,155 |
348 |
2.32*** |
1,302 |
359 |
−2.63*** |
1,186 |
5,757 |
−1.07** |
|
hsa-miR-130b |
5,700 |
8,316 |
−0.46 |
13,023 |
13,880 |
0.07 |
9,994 |
14,055 |
0.41 |
12,053 |
12,432 |
0.03 |
|
hsa-miR-455 |
2,677 |
2,604 |
−0.03 |
3,944 |
5,285 |
0.34* |
3,437 |
5,927 |
0.72** |
3,262 |
5,342 |
0.64* |
|
b |
ME-15 |
HuH7 |
|||||||||||
4 h |
24 h |
4 h |
24 h |
||||||||||
−IFNa |
+IFNa |
CHF |
−IFNa |
+IFNa |
CHF |
−IFNa |
+IFNa |
CHF |
−IFNa |
+IFNa |
CHF |
||
Interferon-regulated microRNAs |
|||||||||||||
hsa-miR-33b |
1,226 |
3,484 |
1.84** |
2,888 |
2,318 |
−0.25 |
476 |
1,113 |
1.34** |
1,306 |
1,851 |
0.42*** |
|
hsa-miR-33 |
2,631 |
7,352 |
1.79 |
9,774 |
5,764 |
−0.70* |
1,887 |
6,645 |
2.52. |
8,893 |
2,726 |
−2.26 |
|
hsa-miR-126* |
2,221 |
5,409 |
1.44* |
5,578 |
6,111 |
0.10 |
4,749 |
6,410 |
0.35. |
5,687 |
5,803 |
0.02*** |
|
hsa-miR-10b |
1,695 |
3,564 |
1.10* |
2,929 |
4,297 |
0.47** |
378 |
411 |
0.09 |
371 |
382 |
0.03 |
|
hsa-miR-551b |
2,085 |
4,169 |
1.00* |
4,423 |
3,419 |
−0.29 |
1,804 |
4,979 |
1.76* |
5,221 |
4,865 |
−0.07 |
|
hsa-miR-137 |
1,037 |
1,966 |
0.90 |
2,523 |
2,872 |
0.14 |
1,613 |
3,155 |
0.96** |
3,429 |
3,598 |
0.05 |
|
hsa-miR-138 |
2,158 |
4,074 |
0.89* |
4,709 |
3,701 |
−0.27 |
725 |
828 |
0.14 |
903 |
859 |
−0.05 |
|
hsa-miR-130b |
5,700 |
9,994 |
0.75 |
13,023 |
12,053 |
−0.08 |
8,316 |
14,055 |
0.69** |
13,880 |
12,432 |
−0.12 |
|
hsa-miR-101 |
6,701 |
11,387 |
0.70 |
13,088 |
11,688 |
−0.12 |
3,569 |
10,871 |
2.05** |
10,445 |
10,796 |
0.03 |
|
hsa-miR-140 |
7,339 |
12,236 |
0.67 |
15,512 |
15,931 |
0.03 |
3,058 |
5,976 |
0.95* |
6,135 |
7,221 |
0.18 |
|
HS_92 |
829 |
1,356 |
0.64. |
1,246 |
1,179 |
−0.06 |
407 |
587 |
0.44 |
492 |
478 |
−0.03 |
|
hsa-miR-362 |
1,382 |
2,234 |
0.62* |
2,144 |
2,276 |
0.06 |
1,907 |
2,737 |
0.43* |
2,456 |
2,519 |
0.03 |
|
hsa-miR-19b |
13,365 |
21,532 |
0.61** |
25,463 |
18,039 |
−0.41 |
9,406 |
20,625 |
1.19* |
22,438 |
17,440 |
−0.29 |
|
hsa-miR-130a |
13,031 |
20,878 |
0.60. |
27,571 |
23,048 |
−0.20 |
17,884 |
31,012 |
0.73* |
33,801 |
28,875 |
−0.17 |
|
hsa-miR-579 |
552 |
816 |
0.48. |
992 |
1,053 |
0.06 |
729 |
1,362 |
0.87* |
1,250 |
1,308 |
0.05 |
|
hsa-miR-29b |
23,138 |
34,148 |
0.48. |
32,691 |
29,710 |
−0.10 |
8,737 |
17,989 |
1.06* |
20,599 |
17,405 |
−0.18. |
|
hsa-miR-19a |
13,617 |
19,226 |
0.41* |
18,318 |
14,425 |
−0.27 |
6,726 |
17,409 |
1.59. |
17,178 |
14,079 |
−0.22. |
|
hsa-miR-338 |
1,298 |
1,813 |
0.40. |
1,870 |
1,603 |
−0.17 |
2,363 |
4,603 |
0.95. |
5,109 |
4,088 |
-0.25 |
|
hsa-miR-590 |
1,403 |
1,949 |
0.39. |
1,545 |
1,367 |
−0.13 |
669 |
1,068 |
0.60. |
884 |
847 |
−0.04 |
|
hsa-miR-545 |
1,455 |
1,973 |
0.36. |
2,149 |
1,720 |
−0.25* |
829 |
1,371 |
0.65** |
1,573 |
1,393 |
−0.13 |
|
hsa-miR-30e-5p |
9,497 |
12,643 |
0.33 |
13,045 |
132,030 |
0.01 |
6,838 |
10,887 |
0.59* |
11,321 |
11,809 |
0.04 |
|
hsa-miR-570 |
1,989 |
2,576 |
0.30. |
2,397 |
2,610 |
0.09 |
2,213 |
3,739 |
0.69* |
4,312 |
3,708 |
−0.16 |
|
hsa-miR-301 |
13,621 |
17,531 |
0.29* |
16,321 |
15,142 |
−0.08 |
5,646 |
10,460 |
0.85* |
10,925 |
10,295 |
−0.06. |
|
hsa-miR-561 |
517 |
621 |
0.20 |
568 |
464 |
−0.22** |
683 |
1,157 |
0.69** |
1,149 |
941 |
−0.22 |
|
HS_250 |
4,284 |
1,813 |
−1.36. |
740 |
983 |
0.33 |
3,688 |
2,337 |
−0.58 |
1,195 |
1,303 |
0.09 |
|
c |
ME-15 |
HuH7 |
|||||||||||
4 h |
24 h |
4 h |
24 h |
||||||||||
−IFNa |
+IFNa |
CHF |
−IFNa |
+IFNa |
CHF |
−IFNa |
+IFNa |
CHF |
−IFNa |
+IFNa |
CHF |
||
Validated microRNAs |
|||||||||||||
hsa-miR-19a |
13,617 |
19,226 |
0.41* |
18,318 |
14,425 |
−0.27 |
6,726 |
17,409 |
1.59. |
17,178 |
14,079 |
−0.22 |
|
hsa-miR-19b |
13,365 |
21,532 |
0.61** |
25,463 |
18,039 |
−0.41 |
9,406 |
20,625 |
1.19* |
22,438 |
17,440 |
−0.29. |
|
hsa-miR-30e-5p |
9,497 |
12,643 |
0.33 |
13,045 |
13,230 |
0.01 |
6,838 |
10,887 |
0.59* |
11,321 |
11,809 |
0.04 |
|
hsa-let-7a |
15,244 |
22,226 |
0.46 |
28,304 |
30,449 |
0.08 |
4,335 |
6,386 |
0.47. |
6,181 |
5,612 |
−0.10 |
|
hsa-let-7b |
8,236 |
12,150 |
0.48* |
12,563 |
2,309 |
−0.02 |
539 |
500 |
−0.08 |
475 |
452 |
−0.05 |
|
hsa-miR-203 |
907 |
1,302 |
0.44* |
1,155 |
1,186 |
0.03 |
325 |
359 |
0.10 |
348 |
575 |
0.665** |
microRNA levels were measured using TaqMan® microRNA assays (Applied Biosystems) using the TaqMan® MicroRNA reverse transcription (RT) kit with TaqMan® 2× universal PCR master mix (No AmpErase® UNG) as recommended by the supplier. Ten nanograms of total RNA was used as input for amplification using the samples used for microarray analysis. Reversed transcriptase products were diluted 1:15 and measured on an ABI 7900HT fast real-time PCR system. Technical replicates were run on three different plates (one with 40 cycles and two with 50 cycles) and threshold for cycling time (CT) calculation was set for all probes to 0.2. For estimation of endogenous small RNA content, the nucleolar RNA RNU48 was used as control and reference.
Standard error (Δx) was calculated by the average standard error of treated and untreated MNE for biological replicates.
The following technical aspects have to be considered for result interpretation. The dataset of the microRNA bead array assay is not directly comparable to gene expression arrays where in vitro translated transcripts are directly hybridized to the probes. Moreover Illumina’s bead array technology tends to have higher background fluorescence levels and lower change factor values than Genechips from Affymetrix. Background (average of negative control signals) and noise (standard deviation of negative probes from each sample) were 528 ± 60 and 229 ± 67, respectively. The density of all samples shows a bimodal distribution peaking around the background fluorescent levels and the robust levels (approximately 12,000). The curve is skewed to the right and peak density height is found in the ratio 4:1 considering all probes (data not shown). The distribution of probes detected in all samples (detection p value threshold at 0.01) has a plateau ranging from about 2,000 close to the detectors maximum capacity of 2^16 relative fluorescent units (12). As expected, the correlation of data coming from biological replicates r² = 0.952 ± 0.028 (not normalized) and r² = 0.956 ± 0.022 (after loess normalization and log-transformation) was lower than for technical replicates r² > 0.97 (12). We preferred loess normalization to quantile normalization because the later was too aggressive for the given small probe numbers.
As a first step we wished to address the robustness of the microRNA array in probe detection by selecting microRNA genes that are detected under all experimental conditions with high statistical significance in all biological triplicates (detection p value < 0.01). In each set of triplicate samples (control, 4 h or 24 h, IFNα stimulation) we detect approximately 270 genes that fulfill the above criteria. This corresponds to roughly a third of microRNAs available for detection in the assay system. Furthermore, this result suggests indirectly that IFNα treatment does not induce global changes in microRNA gene expression, but it modulates rather the expression of individual genes.
Bead-array-based microRNA detection technology, including the bio-statistic analysis, is currently not well established or widely used and we have applied a commercial PCR-based assay to confirm the array data for some microRNAs that cover different expression levels and change factors. In contrast to mRNA profiling, where RT-PCR-based assays are considered as gold standard for data validation, new generation deep sequencing is considered as the method of choice for microRNA quantification but is not available in our research institute. For the microRNAs let-7 a/b, miR-19 a/b, and miR-203, the PCR-based quantification method (Fig. 2b) confirmed the direction of change found with microarray technology (Table 2a). Expression of miR-130b and miR-455 was at similar levels in both assays. The correlation calculated for the eight tested microRNAs was acceptable: multiple r² from f test of mean relative cycling times (ΔCT) to mean log2 microarray expression values was 0.9279. Differences of absolute levels between the microRNA targets probably results from different hybridization properties of the microarray probes and variation in the performance of Taqman primers for the specific microRNA on the other side.
Assuming that any IFNα relevant microRNA will have the same kinetics as the mRNA for PRGs, we looked at the regulation of microRNA genes in our experiment. These IRmiRs should respond to IFNα stimulation preferentially in both cell lines, because this would be a good indication of a general mechanism in the IFNα response. Within the 25 most significantly regulated genes (Table 2b), only one gene (HS_250) is downregulated. A general upregulation of transcripts is consistent with classic IFNα signaling seen for mRNAs. However, the maximal observed change factor with high significance was 1.84 (miR-33b in Table 2b) which is clearly lower than the values seen for protein coding mRNAs (2). We also included an expression analysis 24 h after IFNα stimulation in order to detect microRNA genes that show either delayed induction or remain activated at comparable levels to the 4 h stimulus. Based on our data set, the majority of the microRNA response genes show no further induction, but rather moderate downregulation 24 h after induction. This finding is not surprising as we expected immediate early impact of IFNα-mediated primary signaling.
Some technology-related questions remain open. The microRNA assay measures essentially the number of amplicons generated by RT-PCR for each transcript. Thus the signal is an indirect measurement of transcript abundance as compared to classical mRNA microarray platforms, where the target mRNA is directly labeled during linear amplification by in vitro transcription. As a consequence, change factor calculations for amplicon-based assays are ambiguous.
In summary, Illumina’s bead array technology is well suited for multi-parallel profiling of microRNAs expressed in different cell types or tissues. We were also able to detect IFNα-inducible microRNA genes although the changes observed were moderate and biological significance remains to be proven. Like most microarray-based detection technologies the technical variability among identical samples is low compared to biological variations of individual cell cultures. At this point it is important to note that variation among biological samples occurs and is independent of the parameters that are measured. Consistent with IFNα-dependent induction of mRNAs we find that virtually all modulated microRNA genes are upregulated. However, the IFNα-induced changes detected in our study are relatively small compared to the changes induced by IFNβ in HuH7 cells (9). Finally, it is noteworthy that IRmiRs have similar kinetic properties to their mRNA counterparts. miR-10b for instance is induced early in ME-15 and remains upregulated, while miR-19 abundance ceases after 24 h. In general, the majority of IRmiR genes were reset to basal levels after 24 h and further studies are needed for kinetic classification. Thus, our study adds another level of complexity to the dynamic regulation IFNα signaling and other mechanisms like epigenetic promoter methylation are currently under intense investigation in our laboratories.
更有优质直播、研选好物、福利活动等你来!
本网站所有注明“来源:丁香园”的文字、图片和音视频资料,版权均属于丁香园所有,非经授权,任何媒体、网站或个人不得转载,授权转载时须注明“来源:丁香园”。本网所有转载文章系出于传递更多信息之目的,且明确注明来源和作者,不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
我的询价